Home | Publications | Drug Discovery place holder
place holder place holder

Drug Discovery

Model Animal Systems

Emerging Applications and Commercial Opportunities in Drug Discovery and Development

Publication Date   June 2004
Publisher   Cambridge Healthtech Advisors
Product Type   Report
Pages   124
ISBN Number   not applicable
Product Code   CHA005
Ask a question about this product?

Price £1,946.00

approximately: $3,636 | €2,468

Summary


Model Animal Systems: Emerging Applications and Commercial Opportunities in Drug Discovery and Development reviews the progress in the application of animal models to drug discovery and development, and discusses the leading companies providing tools in this field, the areas of greatest unmet need, and the most important emerging applications. Models discussed include yeast, the nematode (Caenorhabditis elegans), the fruitfly (Drosophila melanogaster), the zebrafish (Danio rerio), the mouse, and the rat.

Experts in the pharmaceutical industry, as well as some at the U.S. Food and Drug Administration (FDA), have identified inadequate animal models as being one of the major hurdles in drug discovery and development. As a result, there has been a surge in the development of such models as well as in the number of commercial ventures built around model organisms. This has led to substantial increase both in the range of animals available and the uses for them. Most importantly, the availability of huge amounts of sequence and variation data on model organisms has helped scientists learn which systems are best applied in what circumstances. Finally, the number of animal models that are available for certain diseases has also increased.

Model Animal Systems: Emerging Applications and Commercial Opportunities in Drug Discovery and Development evaluates these developments, and focuses on the following key issues driving growth in this area:

The use of model organisms in drug discovery and development, specifically in target discovery and evaluation, drug screening, and preclinical studies.

The development of disease-specific models—one of the key areas of unmet need in drug discovery and development. This report includes case studies on the use of model organisms in several important areas:

> Aging and diseases of aging.
> Neurodegenerative diseases.
> Developmental models and their applications to disease pathways.
> Cancer models.

The major model organisms that are relevant to human medicine, leading model organism technology companies and academic laboratories, and their technologies.

Content


Chapter 1. The Emergence of Model Organisms as Critical R&D Tools

1.1. Introduction of Model Organisms into Drug Discovery
1.2. Current Uses of Model Organisms
1.3. Chemical Genetics

Chapter 2. Leading Model Organisms, Companies, and Technologies

2.1 Yeast (Saccharomyces cerevisiae and Schizosaccahromyces pombe)
2.2 Invertebrate Model Organisms (C. elegans and Drosophila)
2.3 Leading Companies Specializing in Use of Invertebrate Model Organisms
DeveloGen
Devgen
Exelixis
Union Biometrica
2.4 The Emerging Importance of the Zebrafish (Danio rerio)
DanioLabs
Phylonix
Zygogen
2.5 Mammalian Systems
Knockout Mouse Technology/Lexicon Genetics
Cellular Genomics’ Analogue-Sensitive Kinase Alleles (ASKAs)
Large-Scale Forward Mouse and Rat Genetics: Ingenium and Phenomix
Transgenic Mouse Models
Xenogen’s Biophotonic Imaging

Chapter 3. Case Studies on the Use of Model Organisms in Development of Therapeutic Strategies

3.1 Model Organisms in Development of Therapeutic Strategies for Diseases of Aging
BioMarker Pharmaceuticals
Chronogen
Eukarion
3.2 Model Organisms in Development of Therapeutic Strategies for Neurodegenerative Diseases
Recent Studies with Model Organisms
3.3 Recent Developments in Mouse Models of Cancer
Lung Cancer Models
A Model for Melanoma and the Concept of “Tumor Maintenance”
Other Mouse Models of Cancer Involving INK4a/ARF
GenPath Pharmaceuticals and Mouse Models of Cancer
3.4 Creating Animal Models of Human Disease Pathways
The Canonical Wnt Pathway
Zebrafish Development and Disease Pathways

Chapter 4. Business and Strategic Issues

4.1. Expert Commentaries
Thierry Bogaert, PhD, Devgen
Dalia Cohen, Novartis
Richard Glynne, Phenomix
Paul Goldsmith, PhD, DanioLabs
Chaoyong Ma, PhD, MBA, Phylonix Pharmaceuticals, Inc.
Michael C. Nehls, MD, PhD, Ingenium Pharmaceuticals
Greg Plowman, Exelixis
Ann Sluder, Cambria Biosciences
Brian P. Zambrowicz, Lexicon Genetics
4.2. Company Profiles
BioMarker Pharmaceuticals, Inc.
Cambria Biosciences
Cellular Genomics Inc. (CGI)
Chronogen, Inc.
DanioLabs
DeveloGen
DevGen
Elixir Pharmaceuticals
Eukarion, Inc.
Exelixis
GenPath Pharmaceuticals
Ingenium Pharmaceuticals
The Jackson Laboratory
Lexicon Genetics
Novartis
Phenomix
Phylonix Pharmaceuticals, Inc.
Union Biometrica
The Wellcome Trust
Wyeth
Xenogen
Zygogen


Glossary